RNAi的抗病毒机制及应用

RNA干扰(RNA interference,RNAi)能够在转录水平、翻译水平和转录后水平上抑制病毒的复制,这为临床治疗病毒性疾病奠定了理论基础。近年来,RNAi技术发展迅速,使得RNAi技术应用于病毒性疾病的治疗成为可能。本文从RNAi抗病毒的作用机制及RNAi在抗动物病毒性疾病方面的应用等方面进行综述,并对RNAi在抗病毒方面的应用前景进行展望。     

RNA干扰用于基因治疗的研究进展

RNA干扰(RNAi)是20世纪末才被人们认识和重视的一种通过双链RNA抵御病毒入侵或抑制转座子活动的生物防御机制。随着RNA干扰分子机制研究的深入及其应用研究的发展,人们发现RNA干扰技术在基因功能研究及人类疾病的基因治疗上具有广阔的应用前景。本文在简述RNAi分子机制的基础上,综述了RNAi在抗病毒治疗及抗肿瘤治疗方面的研究和应用概况。     

RNA干涉的临床前实验研究进展

RNA干涉（RNA interference,RNAi）是一种非常保守的细胞现象,在基础研究和疾病治疗方面具有重大的应用前景。尤其引人注目的是,新的RNAi方法学与已建立的转基因策略相结合,有效地将组织特异性RNAi导入到患者体内,有望治疗人类疾病。本文综述了RNAi的机制与在其临床前的实验研究,简要介绍了RNAi的新用途,讨论了RNAi基因治疗存在的问题,展望了RNAi基因治疗的应用前景。     

植物小RNA与RNA干扰：生物学功能与应用前景

RNA干扰（RNAi）的发现使人们对基因调控有了新的认识,同时它也逐渐发展为遗传分析、疾病治疗以及植物保护等方面一种非常有用的新技术.本文重点介绍RNAi的生物学功能及其在农业上的应用前景.为更好地了解RNAi,本文还简要回顾了RNAi的发现历史并简单阐述小RNA生成途径和RNAi的分子机制.     

RNA干扰技术在基因治疗中的应用进展

RNA干扰(RNA interference,RNAi)是一种双链RNA分子在mRNA水平上关闭相应序列基因的表达或使其沉默的过程,在基因治疗方面有着无可比拟的优势,已成功的应用于肿瘤、病毒感染、遗传性疾病及神经系统疾病等重大疾病的治疗.本文将主要介绍siRNA基因治疗的导入方法与途径,以及在不同疾病中,RNAi技术进行基因治疗的应用.     

RNA干扰的机制及其应用

RNA干扰(RNA interference,RNAi)是真核生物中高度保守的,由小分子干扰RNA(small interfering RNA,si RNA)介导的转录后基因沉默现象,在基因功能的研究中得到了非常广泛的应用,并有望成为小核酸药物在疾病治疗中发挥重要作用。现对近年来RNAi的作用机制、si RNA的产生途径、引起RNAi副作用的原因以及RNAi表达载体的设计这四个方面的国内外研究进展进行了总结,对RNAi与CRISPR技术在应用中的关系进行了探讨,展望了RNAi技术未来的发展。     

RNAi技术的医疗应用潜力

RNA干扰是指双链RNA在细胞内特异性地诱导同源互补的mRNA降解,从而阻断相应基因表达的现象。RNAi发展成为一种新型的基因治疗方式的进程取决于哺乳动物砌RNAi的研究进展。在大多数哺乳动物细胞中,直接导入长dsRNA引发的非特异性基因沉默掩盖了RNAi效应,而多种有效的双链RNA导入方式在一定程度上解决了这一问题。初步的实验结果表明,用RNAi治疗癌症、病毒感染等疾病的设想有可能变成现实。     

RNA干扰技术及其在动物疾病研究中的应用

RNA干扰(RNA interference)是存在于真核细胞中的基因特异性沉默机制,可以抑制病毒抗原基因的表达或抵御转座子转座。自从发现以来,RNAi技术已在基因的功能性研究上显示出了强大的优势,特别是在动物病毒性疾病的治疗和预防上,相对于传统的疫苗预防和药物治疗有着无可比拟的优越性。在动物细胞中转入针对特异病毒的小干扰RNA(siRNA)或短发卡RNA(shRNA)激活RNAi通路可有效抑制病毒的复制。阐述RNA干扰的发生机制及其在动物疾病防治中的应用。     

RNA干扰技术治疗疾病

RNA干扰(RNA interference,RNAi)现象最早发现于秀丽隐杆线虫(Caenorhabditis elegans),随后发现该现象普遍存在于真菌、植物和哺乳动物等真核生物,并行使基因调控和抵御外源基因片段侵袭的作用。目前,RNAi分子机制和RNAi在基因功能方面的研究已经取得了突破性的进展。鉴于RNAi在基因沉默中的特异性、高效性和易操作,其在药物筛选和疾病治疗等方面有着广泛的应用前景。然而,RNAi技术用于治疗疾病的安全性尚待确定,分子传递途径也有待进一步的研究。     

RNA干扰药物用于疾病治疗的安全性问题

RNA干扰（RNA interference,RNAi）是指由双链RNA介导的序列特异的转录后基因沉默。RNAi技术因其特异性、高效性而备受青睐,在疾病治疗方面表现出广阔的应用前景。然而,近年来的研究发现,基于RNAi技术开发的药物存在安全性问题,主要包括引起免疫反应、产生脱靶效应、以及存在竞争微RNA通路等。这些问题的突破将使RNAi技术获得更加广泛的应用。     

RNAi在抗病毒防治领域的应用

RNAi是由双链RNA(dsRNA)所诱发的转录后水平上的基因沉默.由于对靶基因沉默作用的高度特异性和高效性,因此近年来用于肿瘤性疾病、感染性疾病、遗传性疾病等疾病的基因治疗研究,特别是在抗病毒领域的研究更是成为其应用热点之一.虽然目前RNAi已经较为广泛地应用于动物病毒及各种疾病病毒的基因治疗研究中,但其在应用过程中还有许多亟待解决的问题.本文就RNAi及其在抗病毒领域的应用研究和其存在的问题展开综述.     

Inhibition of hepatitis B virus in mice by RNA interference

Hepatitis B virus (HBV) infection substantially increases the risk of chronic liver disease and hepatocellular carcinoma in humans. RNA interference (RNAi) of virus-specific genes has emerged as a potential antiviral mechanism. Here we show that RNAi can be applied to inhibit production of HBV replicative intermediates in cell culture and in immunocompetent and immunodeficient mice transfected with an HBV plasmid. Cotransfection with plasmids expressing short hairpin RNAs (shRNAs) homologous to HBV mRNAs induced an RNAi response. Northern and Southern analyses of mouse liver RNA and DNA showed substantially reduced levels of HBV RNAs and replicated HBV genomes upon RNAi treatment. Secreted HBV surface antigen (HBsAg) was reduced by 94.2% in cell culture and 84.5% in mouse serum, whereas immunohistochemical detection of HBV core antigen (HBcAg) revealed >99% reduction in stained hepatocytes upon RNAi treatment. Thus, RNAi effectively inhibited replication initiation in cultured cells and mammalian liver, showing that such an approach could be useful in the treatment of viral diseases.     

RNA干扰技术在水产动物抗病毒和抗寄生虫研究中的应用研究进展

RNA干扰(RNA interference,RNAi)是由双链RNA介导的,抑制目标基因的表达,沉默靶基因的一种转录后基因沉默机制,并且在真核生物中广泛存在。近年来随着水产养殖业的发展壮大,水产动物疾病频繁爆发,给养殖户带来巨大的经济损失。目前,病毒、寄生虫等病原引起的水产动物疾病的致病机制还有待深入研究。RNA干扰技术的出现为水产动物疾病致病机制的研究提供了强有力的工具。主要对RNA干扰的发现、作用机制以及在水产动物抗病毒和抗寄生虫研究中的应用作以综述,并对未来RNAi技术在水产动物疾病防治中的研究和应用进行了展望,旨为水产动物疾病控制提供参考。     

RNAi的作用机制及其临床应用研究

RNAi是指在特定因子的作用下,由导入细胞内的双链RNA(dsRNA)降解成的约22nt左右的siRNA。是近年来发现的可被人工诱导的一种生物体自身所具有的基因沉默现象。因为其相对于其他类似手段有更为突出的高效性、高特异性等优点,而越来越受到人们的重视。已经迅速发展成为研究基因功能的重要工具,并将在对病毒病、肿瘤病、遗传病等的治疗方面发挥着重要作用,因此被《Science》评选为2002年度最重要的科技突破。然而作为一种新的技术它仍有一些不足亟待完善,而在临床应用方面需要进一步深入的研究和验证。     

RNA interference in infectious tropical diseases

Introduction of double-stranded RNA (dsRNA) into some cells or organisms results in degradation of its homologous mRNA, a process called RNA interference (RNAi). The dsRNAs are processed into short interfering RNAs (siRNAs) that subsequently bind to the RNA-induced silencing complex (RISC), causing degradation of target mRNAs. Because of this sequence-specific ability to silence target genes, RNAi has been extensively used to study gene functions and has the potential to control disease pathogens or vectors. With this promise of RNAi to control pathogens and vectors, this paper reviews the current status of RNAi in protozoans, animal parasitic helminths and disease-transmitting vectors, such as insects. Many pathogens and vectors cause severe parasitic diseases in tropical regions and it is difficult to control once the host has been invaded. Intracellularly, RNAi can be highly effective in impeding parasitic development and proliferation within the host. To fully realize its potential as a means to control tropical diseases, appropriate delivery methods for RNAi should be developed, and possible off-target effects should be minimized for specific gene suppression. RNAi can also be utilized to reduce vector competence to interfere with disease transmission, as genes critical for pathogenesis of tropical diseases are knockdowned via RNAi.     

Stable inhibition of hepatitis B virus proteins by small interfering RNA expressed from viral vectors

BACKGROUND: There has been much research into the use of RNA interference (RNAi) for the treatment of human diseases. Many viruses, including hepatitis B virus (HBV), are susceptible to inhibition by this mechanism. However, for RNAi to be effective therapeutically, a suitable delivery system is required. METHODS: Here we identify an RNAi sequence active against the HBV surface antigen (HBsAg), and demonstrate its expression from a polymerase III expression cassette. The expression cassette was inserted into two different vector systems, based on either prototype foamy virus (PFV) or adeno-associated virus (AAV), both of which are non-pathogenic and capable of integration into cellular DNA. The vectors containing the HBV-targeted RNAi molecule were introduced into 293T.HBs cells, a cell line stably expressing HBsAg. The vectors were also assessed in HepG2.2.15 cells, which secrete infectious HBV virions. RESULTS: Seven days post-transduction, a knockdown of HBsAg by approximately 90%, compared with controls, was detected in 293T.HBs cells transduced by shRNA encoding PFV and AAV vectors. This reduction has been observed up to 5 months post-transduction in single cell clones. Both vectors successfully inhibited HBsAg expression from HepG2.2.15 cells even in the presence of HBV replication. RT-PCR of RNA extracted from these cells showed a reduction in the level of HBV pre-genomic RNA, an essential replication intermediate and messenger RNA for HBV core and polymerase proteins, as well as the HBsAg messenger RNA. CONCLUSIONS: This work is the first to demonstrate that delivery of RNAi by viral vectors has therapeutic potential for chronic HBV infection and establishes the ground work for the use of such vectors in vivo.     

RNA干扰在疾病治疗方面的应用研究

RNA干扰是由双链RNA引起的序列特异的基因沉默现象。由于RNA干扰能在细胞组织及动物模型中沉默疾病相关基因,因此,RNA干扰也是各种疾病治疗的有效手段。在哺乳动物细胞内诱导RNA干扰可以通过导入小干扰RNA（siRNA）,或是以质粒、病毒为载体表达短的发夹RNA（shRNA）而实现。本文介绍了RNA干扰在疾病治疗方面的应用,并就其面临的挑战进行讨论。